Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2015

01.08.2015 | case report

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

verfasst von: Univ. Doz. Dr. med. univ Arno Amann, Dr. Normann Steiner, Eberhard Gunsilius

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

Background

Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far.

Case report

Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5 mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit.

Results

Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess.

Conclusion

Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments.
Literatur
1.
Zurück zum Zitat Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Elsässer A, Kühnel T, et al. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). VASA. 2013;42:106–10.CrossRefPubMed Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Elsässer A, Kühnel T, et al. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). VASA. 2013;42:106–10.CrossRefPubMed
2.
Zurück zum Zitat Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost. 2010;8:1447–56.CrossRefPubMed Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost. 2010;8:1447–56.CrossRefPubMed
3.
Zurück zum Zitat Hsu CC-T, Kwan GNC, Thompson SA, Evans-Barns H, van Driel ML. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev. 2012;8:CD008017.PubMed Hsu CC-T, Kwan GNC, Thompson SA, Evans-Barns H, van Driel ML. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev. 2012;8:CD008017.PubMed
4.
Zurück zum Zitat Buscarini E, Buscarini L, Civardi G, Arruzzoli S, Bossalini G, Piantanida M. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol. 1994;163:1105–10.CrossRefPubMed Buscarini E, Buscarini L, Civardi G, Arruzzoli S, Bossalini G, Piantanida M. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol. 1994;163:1105–10.CrossRefPubMed
5.
Zurück zum Zitat Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol. 1999;13:319–22.CrossRefPubMed Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol. 1999;13:319–22.CrossRefPubMed
6.
Zurück zum Zitat Sargeant IR, Loizou LA, Rampton D, Tulloch M, Bown SG. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut. 1993;34:470–5.PubMedCentralCrossRefPubMed Sargeant IR, Loizou LA, Rampton D, Tulloch M, Bown SG. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut. 1993;34:470–5.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Fukushima H, Mitsuhashi T, Oto T, Sano Y, Kusano KF, Goto K, et al. Successful lung transplantation in a case with diffuse pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Am J Transplant. 2013;13:3278–81.CrossRefPubMed Fukushima H, Mitsuhashi T, Oto T, Sano Y, Kusano KF, Goto K, et al. Successful lung transplantation in a case with diffuse pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Am J Transplant. 2013;13:3278–81.CrossRefPubMed
8.
Zurück zum Zitat Sadick H, Bergler WF, Oulmi-Kagermann J, Naim R, Sadick M, Hörmann K, et al. Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res. 2005;36:468–73.CrossRefPubMed Sadick H, Bergler WF, Oulmi-Kagermann J, Naim R, Sadick M, Hörmann K, et al. Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res. 2005;36:468–73.CrossRefPubMed
9.
Zurück zum Zitat Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia—a long-term clinical trial. Rhinology. 2011;49:214–6.PubMed Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia—a long-term clinical trial. Rhinology. 2011;49:214–6.PubMed
10.
Zurück zum Zitat Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron P-Y, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12:1494–502.CrossRefPubMed Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron P-Y, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12:1494–502.CrossRefPubMed
11.
Zurück zum Zitat Dupuis-Girod S, Ginon I, Saurin J-C, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948–55.CrossRefPubMed Dupuis-Girod S, Ginon I, Saurin J-C, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948–55.CrossRefPubMed
12.
Zurück zum Zitat Kjeldsen AD, Tørring PM, Nissen H, Andersen PE. Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia. Acta Neurol Scand. 2014;129:192–7.CrossRefPubMed Kjeldsen AD, Tørring PM, Nissen H, Andersen PE. Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia. Acta Neurol Scand. 2014;129:192–7.CrossRefPubMed
13.
Zurück zum Zitat Mathis S, Dupuis-Girod S, Plauchu H, Giroud M, Barroso B, Ly KH, et al. Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. Clin Neurol Neurosurg. 2012;114:235–40.CrossRefPubMed Mathis S, Dupuis-Girod S, Plauchu H, Giroud M, Barroso B, Ly KH, et al. Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. Clin Neurol Neurosurg. 2012;114:235–40.CrossRefPubMed
Metadaten
Titel
Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia
verfasst von
Univ. Doz. Dr. med. univ Arno Amann
Dr. Normann Steiner
Eberhard Gunsilius
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0789-4

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen